ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0375

Patient Outcomes During the Implementation of a Patient Decision-Aid for a Diverse Population of Systemic Lupus Erythematosus: A Study in 15 U.S. Rheumatology Clinics

Jasvinder Singh1, Larry Hearld2, Walter Chatham3, Sonali Narain4, Narender Annapureddy5, Diane Kamen6, Kimberly Trotter7, vikas Majithia8, Zineb Aouhab9, Swamy Venuturupalli10, Daniel Wallace11, rosalind Ramsey-Goldman12, Alfred Kim13, Maureen McMahon14, S. Sam Lim15, Kalpana Bhairavarasu16, Alexa Meara17, Kenneth Kalunian18 and Cathy Lee Ching19, 1Baylor College of Medicine, Birmingham, AL, 2University of Alabama at Birmingham (UAB), Birmingham, AL, 3University of Nevada, Las Vegas, Las Vegas, NV, 4Northwell Health, Great Neck, NY, 5Vanderbilt University Medical Center, Nashville, TN, 6Medical University of South Carolina, Charleston, SC, 7University of Chicago, Chicago, IL, 8University of Missisippi Medical Center (UMC), Jackson, MS, 9Loyola University Medical Center, Oak Brook, IL, 10Attune Health, Beverly Hills, CA, 11Cedars Sinai Medical Center, Studio City, CA, 12Northwestern University, Chicago, IL, 13Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, 14UCLA David Geffen School of Medicine, Los Angeles, CA, 15Emory University, Atlanta, GA, 16Baylor College of Medicine, Sugar Land, TX, 17The Ohio State University Wexner Medical Center, COLUMBUS, OH, 18University of California San Diego, La Jolla, CA, 19UMMC, Jackson, MS

Meeting: ACR Convergence 2024

Keywords: Decision analysis, Disparities, Health Care, Health Services Research, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Patient Outcomes, Preferences, & Attitudes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: To implement a self-administered patient decision-aid (PtDA) for lupus in outpatient clinics, assess its reach/penetration within each clinic, and examine patient outcomes

Methods: An effective computerized lupus PtDA was provided through a touchscreen tablet in clinics, a weblink, or as smartphone application, in 15 rheumatology outpatient clinics. We examined penetration/reach in the clinic. Secondary outcomes at baseline, 12- and 24-month follow-up based on validated surveys included: (1) Patient decisional conflict (score range 0-100; lower score is better); (2) shared decision-making (SDM) with Control Preferences Scale (CPS) that assesses the concordance between patient’s preferred and actual role in managing lupus was assessed with 2-item (percent agreement; range, 0-100%; higher % agreement indicating better SDM); (3) patient involvement in SDM on 3-item CollaboRATE scale (score range 0-27; higher score indicating better involvement and understanding); (4) patient-physician communication using Inter-personal Processes of Care Short Form (IPC-SF; 18-item; score range 18-90; higher scores indicating better care process); and (5) patient satisfaction using 1-item (score range 1-5, higher scores indicating higher satisfaction).

 

Results: Among 15 geographically diverse U.S. rheumatology clinics, 1,773 patients viewed the lupus PtDA during regular clinic visits. The penetration/reach (primary outcome) ranged from 9% to 60%. We found that the total number of providers in the clinic was positively associated with higher clinic penetration.

Post-PtDA view patient outcomes (n=1,773) were good-excellent at baseline: (1) Low decision conflict scale (DCS) score of 19.5 (range 0-100;); (2) 82.4% matched with regards to their preferred role to play versus the actual role played in treatment decision-making; (3) patient involvement in SDM, CollaboRATE score was 25.1 (SD, 4.2; range 0-27); (4) patient-physician communication process score, 82.3 (SD, 9; range 18-90); (5) 86.2% were satisfied with the ease of use. Each score persisted at two follow-up visits.

Conclusion: We implemented a patient lupus PtDA dissemination for SDM in 15 geographically diverse sites with varied success rates. Patients reported favorable outcomes using the lupus PtDA. The lupus PtDA app (ManageMyLupus) is now freely available.

Funding:
Research reported in this work was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (SDM-2017C2-8224). The statements in this publication are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors, or the Methodology Committee.


Disclosures: J. Singh: Adaptimmune Therapeutics, 2, Adept Field Solutions, 2, Aebona Pharmaceuticals, 11, Amarin, Viking and Moderna pharmaceuticals, 11, Atai life sciences, Kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, Ad, 11, Charlotte's Web Holdings, 11, Clinical Care options, 2, Enzolytics Inc, 11, Fidia, 2, Focus forward, 2, GeoVax Labs, 11, Intuitive Surgical Inc./Philips Electronics North America, 12, food and beverage payments, Jupiter Life Science, 2, MedIQ, 2, Medscape, 2, Medusas, 2, Navigant consulting, 2, Pieris Pharmaceuticals, 11, PK Med, 2, Practice Point communications, 2, Putnam associates, 2, ROMTech, Atheneum, Clearview healthcare partners, American College of Rheumatology, Yale, Hulio, Horizon Pharmaceuticals/DINORA, Frictionless Solution, 2, Schipher, 2, Seres Therapeutics, 11, speaker’s bureau of Simply Speaking, 6, Tonix Parmaceuticals, 11, Trio Health, 2, Two Labs Inc, 2, UBM LLC, 2, WebMD, 2, Zimmer Biomet Holdings, 5; L. Hearld: None; W. Chatham: None; S. Narain: None; N. Annapureddy: None; D. Kamen: Alpine Immune Sciences, 1, Bristol Myers Squibb (BMS), 1; K. Trotter: None; v. Majithia: None; Z. Aouhab: None; S. Venuturupalli: None; D. Wallace: None; r. Ramsey-Goldman: None; A. Kim: Amgen, 2, ANI Pharmaceuticals, 2, AstraZeneca, 5, Atara Bio, 2, Aurinia Pharmaceuticals, 2, Cargo Therpeutics, 2, Exagen Diagnostics, 2, 6, GSK, 2, 5, 6, Kypha, 2, 4, 10, Miltenyi Biotech, 2, Novartis, 5, Pfizer, 2, Synthekine, 2, Techtonic Therapeutics, 2, The Rheumatology Education Group, 6; M. McMahon: Amgen, 2, Artivia, 2, Astra Zeneca, 6, Aurinia, 6, Bristol-Myers Squibb(BMS), 2, Genentech, 2, GSK, 2, 6; S. Lim: Accordant, 2, AstraZeneca, 2, Biogen, 5, BMS, 5, Gilead, 5, GSK, 2, Novartis, 5, UCB, 5; K. Bhairavarasu: None; A. Meara: None; K. Kalunian: None; C. Lee Ching: None.

To cite this abstract in AMA style:

Singh J, Hearld L, Chatham W, Narain S, Annapureddy N, Kamen D, Trotter K, Majithia v, Aouhab Z, Venuturupalli S, Wallace D, Ramsey-Goldman r, Kim A, McMahon M, Lim S, Bhairavarasu K, Meara A, Kalunian K, Lee Ching C. Patient Outcomes During the Implementation of a Patient Decision-Aid for a Diverse Population of Systemic Lupus Erythematosus: A Study in 15 U.S. Rheumatology Clinics [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/patient-outcomes-during-the-implementation-of-a-patient-decision-aid-for-a-diverse-population-of-systemic-lupus-erythematosus-a-study-in-15-u-s-rheumatology-clinics/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-outcomes-during-the-implementation-of-a-patient-decision-aid-for-a-diverse-population-of-systemic-lupus-erythematosus-a-study-in-15-u-s-rheumatology-clinics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology